Is the current medication regimen appropriate for a patient with major depressive disorder, recurrent, moderate (F33.1), unspecified anxiety disorder (F41.9), and unspecified agoraphobia (F40.00) who is taking sertraline 150 mg orally daily, bupropion extended‑release 300 mg orally daily, aripiprazole 2 mg orally daily, buspirone 10 mg twice daily, mirtazapine 7.5 mg orally as needed for sleep, and propranolol 10 mg orally as needed for situational social anxiety, given that mood has plateaued with low‑grade depressive symptoms, increased irritability, impatience, and episodes of disproportionate anger?

This Regimen Requires Optimization

This polypharmacy regimen is suboptimal and should be streamlined—the patient has plateaued on five concurrent psychotropics with persistent depressive symptoms and new irritability/anger, suggesting either inadequate treatment of the underlying depression or medication-induced mood destabilization that warrants systematic reassessment rather than continued polypharmacy.

Core Problems with Current Approach

The patient is on five standing medications plus two PRNs for moderate recurrent MDD with anxiety—this level of polypharmacy typically indicates sequential failed augmentation attempts rather than evidence-based combination therapy. Most concerning:

• Plateaued response with residual symptoms indicates the current combination isn't working adequately
• New irritability and disproportionate anger may represent akathisia from aripiprazole, serotonergic overstimulation, or undertreated depression with emerging mixed features
• No clear therapeutic rationale for combining sertraline + bupropion + aripiprazole + buspirone simultaneously

Evidence-Based Reassessment Strategy

First: Evaluate the Irritability/Anger

This is the most urgent clinical concern. Consider:

1. Aripiprazole-induced akathisia (even at 2 mg)—presents as inner restlessness, irritability, and agitation. If present, discontinue aripiprazole immediately.

2. Serotonin excess from sertraline 150 mg + mirtazapine (even PRN)—can cause agitation, irritability, restlessness. The combination may be excessive.

3. Activation from bupropion—though typically beneficial, in some patients causes irritability, especially when combined with other activating agents.

4. Undertreated depression with emerging mixed features—persistent low-grade depression can manifest as irritability and anger.

Second: Simplify the Regimen Based on Guidelines

The 2023 ACP guidelines 1 found no significant differences between various antidepressant monotherapies or switch strategies for MDD. When patients don't achieve remission with initial treatment, the evidence shows:

• Switching antidepressants is as effective as augmentation strategies 1
• Augmentation with bupropion or cognitive therapy showed similar efficacy in STAR*D 1
• Augmentation with aripiprazole showed higher remission than bupropion in one trial (55.4% vs 34.0%), but this was a high risk-of-bias study 1

For MDD with prominent anxiety symptoms, recent evidence suggests 2, 3:

• Aripiprazole and brexpiprazole have shown benefit for both depression and anxiety in exploratory analyses
• Mirtazapine may be advantageous when anxiety and sleep disturbance are prominent 3
• Bupropion shows comparable efficacy to SSRIs in most presentations, with modest SSRI advantage only in highly anxious subgroups 4

Recommended Approach

Option 1: Optimize Current SSRI + Augmentation (if irritability is medication-induced)

1. Discontinue aripiprazole (most likely culprit for irritability/anger)
2. Continue sertraline 150 mg (at therapeutic dose per FDA labeling 5)
3. Continue bupropion XL 300 mg (evidence supports this combination 6)
4. Discontinue buspirone (redundant with sertraline for anxiety; limited evidence in this context)
5. Regularize mirtazapine 7.5-15 mg nightly (not PRN)—addresses anxiety, sleep, and may provide additional antidepressant effect 3
6. Continue propranolol PRN (appropriate for situational anxiety)

This reduces from 5 standing medications to 3, with clearer mechanistic rationale: SSRI (serotonin) + bupropion (dopamine/norepinephrine) + mirtazapine (norepinephrine/serotonin with sedation).

Option 2: Switch Strategy (if current combination fundamentally inadequate)

Given the plateau despite multiple agents, consider switching to:

• Venlafaxine XR 150-225 mg (SNRI with robust evidence) OR
• Mirtazapine 30-45 mg as monotherapy (addresses depression, anxiety, and sleep in one agent 3)

Then reassess after 6-8 weeks before adding augmentation.

Option 3: If Irritability Represents Undertreated Depression with Mixed Features

• Discontinue aripiprazole (can worsen mixed states in some patients)
• Optimize sertraline to 200 mg (maximum FDA-approved dose 5)
• Continue bupropion XL 300 mg
• Add lamotrigine (titrate to 200 mg)—better evidence for mood stabilization in depression with irritability than low-dose aripiprazole

Critical Pitfalls to Avoid

1. Don't add another medication without removing something—this patient is already on excessive polypharmacy
2. Don't ignore the new irritability/anger—this is a red flag requiring active intervention, not passive observation
3. Don't continue aripiprazole at 2 mg indefinitely—this subtherapeutic dose for "mood stabilization" lacks strong evidence and may be causing more harm than benefit
4. Don't use mirtazapine PRN—it requires regular dosing for antidepressant/anxiolytic effects; PRN use only provides sedation 3
5. Don't assume buspirone adds value—in the context of adequate SSRI dosing, buspirone augmentation showed no advantage over bupropion augmentation in STAR*D 1

Monitoring Plan

After simplification:

• Week 1-2: Assess for akathisia resolution (if aripiprazole discontinued)
• Week 4: Evaluate irritability, anger, and depressive symptoms
• Week 8: Full reassessment of response using standardized measure (PHQ-9 or MADRS)
• If inadequate response at 8 weeks: Consider switch strategy rather than adding more medications

The goal is remission (not just response), which requires systematic optimization rather than indefinite polypharmacy 1, 7.